Publications by authors named "Xiangping Zong"
Article Synopsis
- Angioimmunoblastic T-cell lymphoma (AITL) has a poor prognosis, and the study aimed to assess the effectiveness and safety of adding chidamide to the standard CHOP treatment for newly diagnosed patients.
- The research involved 66 patients, split evenly between those receiving chidamide with CHOP and those receiving CHOP alone, showing that the chidamide group had significantly better overall survival and progression-free survival rates.
- Additionally, patients who underwent transplantation after treatment showed even longer survival rates, underscoring the potential benefits of chidamide and the importance of considering transplantation in treatment plans.
Article Synopsis
- A clinical study tested a dual-targeted chimeric antigen receptor T (CAR-T) cell therapy combined with an anti-PD-1 antibody (tislelizumab) for treating patients with refractory or relapsed B cell non-Hodgkin lymphoma (R/R B-NHL).
- Out of 16 enrolled patients, 87.5% responded positively, with 68.8% achieving a complete response; the one-year progression-free survival rate was 68.8%, and overall survival was 81.3%.
- The therapy appeared safe, with a significant portion of patients maintaining their response, and immune signaling pathways were notably active in those who responded well to treatment.
Introduction: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) shows poor response rates in non-germinal center B cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) patients with multiple extranodal involvement. This study aims to evaluate anti-tumor activity and safety of zanubrutinib with R-CHOP (ZR-CHOP) in treatment naïve non-GCB DLBCL with extranodal involvement.
Methods: In this single-arm, phase 2, prospective, single-center study, patients with newly diagnosed non-GCB DLBCL with extranodal involvement enrolled between October 2020 to March 2022 received ZR-CHOP for 6 cycles followed by 2 cycles of maintenance treatment with rituximab and zanubrutinib.
Background: Patients with relapsed or refractory (R/R) lymphomas have benefited from chimeric antigen receptor (CAR)-T-cell therapy. However, this treatment is linked to a high frequency of adverse events (AEs), such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematologic toxicity. There has been increasing interest in hematological toxicity in recent years, as it can result in additional complications, such as infection or hemorrhage, which remain intractable.
View Article and Find Full Text PDFBackground: The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge to overcome. Here, we report the clinical results and the pharmacokinetics of bispecific CD19/22 CAR T in patients with R/R B-NHL.
View Article and Find Full Text PDFBackground: Autologous stem-cell transplantation (ASCT) is the standard treatment for R/R B-NHL, while chimeric antigen receptor T (CAR-T) therapy targeting CD19 emerges as an alternative strategy. Here we report a comparative analysis of the two strategies in a single center.
Methods: We performed a prospective single-arm study of CAR-T therapy in 29 patients with R/R B-NHL and compared the outcomes with contemporaneous 27 patients who received ASCT.